Erlotinib, one of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), is active and relatively well tolerated in chemotherapy-naïve elderly patients with advanced non-small cell lung cancer (NSCLC) [1]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.